|Bid||57.61 x 800|
|Ask||57.60 x 4000|
|Day's range||57.51 - 58.60|
|52-week range||46.48 - 60.93|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||38.03|
|Forward dividend & yield||1.40 (2.46%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||65.47|
Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Julie Hyman breaks down Thursday’s business headlines, including: gun manufacturer Remington offering a $33 million settlement to nine families in connection with the 2012 Sandy Hook shooting, Emergent resuming J&J vaccine production in Baltimore, AstraZeneca losing money on its Covid-19 vaccine after vowing to distribute the shot at no profit, and the Ever Given reaching Rotterdam after Suez Canal debacle.
In the darkest days of the coronavirus crisis, Emmanuel Macron took to the media circuit with a scathing attack on the world’s cheapest Covid vaccine – and the only one to be produced at cost. Britain’s pioneering jab, developed by Oxford University and manufactured by AstraZeneca, was “quasi-ineffective” on older people, the French President said. “The real problem on AstraZeneca is that it doesn’t work the way we were expecting it to,” he added. Weeks later, when a study suggested there was a